Longboard Pharmaceuticals to Participate in Five Upcoming Epilepsy-Focused Conferences this SummerGlobeNewsWire • 06/01/22
Longboard Pharmaceuticals to Present Phase 1 Data for LP352 at the American Academy of Neurology Annual MeetingGlobeNewsWire • 04/01/22
Longboard Pharmaceuticals to Participate in Cantor Fitzgerald's Virtual Rare Orphan Disease SummitGlobeNewsWire • 03/23/22
Longboard Pharmaceuticals to Participate in Maxim Group 2022 Virtual Growth ConferenceGlobeNewsWire • 03/22/22
Longboard Pharmaceuticals Announces the Appointment of Highly Accomplished Healthcare Executive Randall Kaye, M.D., as Chief Medical OfficerGlobeNewsWire • 03/21/22
Longboard Pharmaceuticals Provides Corporate Update and Reports Full Year 2021 Financial ResultsGlobeNewsWire • 03/03/22
Longboard Pharmaceuticals, Inc. (LBPH) Could Find Support Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 12/06/21
Longboard Pharmaceuticals Appoints Life Sciences Executive Dr. Jane Tiller to Board of DirectorsGlobeNewsWire • 11/17/21
Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2021 Financial ResultsGlobeNewsWire • 11/04/21
Longboard Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference on September 28, 2021GlobeNewsWire • 09/21/21
Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical TrialGlobeNewsWire • 09/08/21
Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2021 Financial ResultsGlobeNewsWire • 08/09/21
Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2021 Financial ResultsGlobeNewsWire • 05/10/21